ĤÊÜÌåEGFRÀ©ÔöÒÔ¼°ÆäÏÂÓεÄÂç°±ËἤøÐźÅͨ·¼¤»îÊÇÄÔ½ºÖÊÁöµÄÏÔÖøÌØµãÖ®Ò»£¬£¬£¬µ«Î¬³ÖÄÔ½ºÖÊÁöÖÐEGFR³ÖÐøÏ¸°ûĤ¶¨Î»ÒÔ¼°EGFRÐźÅͨ·¼¤»îµÄ»úÖÆÈÔδÍêÈ«Ã÷Îú¡£¡£¡£
¿ËÈÕ£¬£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½ÔºÉñ¾Íâ¿ÆÕÅåó½ÌÊÚ¿ÎÌâ×é·¢Ã÷À´×ÔÓÚEGFR»ùÒòµÄ14¡¢15ÍâÏÔ×ӵĻ·×´RNA»·×´circ-EGFRÔÚÄÔ½ºÖÊÁö¸Éϸ°ûϵ£¨BITC£©ÖÐÏÔÖø¸ß±í´ï£¬£¬£¬ÁÙ´²Ñо¿Ð§¹ûÏÔʾµÍ±í´ïcirc-EGFR»¼ÕßÔ¤ºó¸üºÃ£¬£¬£¬ÌáÐÑÆä×÷Ϊһ¸ö´Ù°©»ùÒòµÄ¿ÉÄÜÐÔ¡£¡£¡£¿ÎÌâ×éͨ¹ý¶Ôcirc-EGFR¾ÙÐÐÔ¤²âÆÊÎö£¬£¬£¬·¢Ã÷»·×´RNAÖаüÀ¨Ò»¸ö¿ª·ÅµÄÎÞÏÞÔĶÁ¿ò£¬£¬£¬¿ÉÒÔ¹ö»··ÒëÒ»¸öеÄÂѰ×Öʸ´ºÏÌåRolling-translated EGFR£¨rtEGFR£©¡£¡£¡£»£»úÖÆÑо¿·¢Ã÷£¬£¬£¬rtEGFRͨ¹ýÁ¬ÏµEGFRά³ÖEGFRĤ¶¨Î»¶ø³ÖÐø¼¤»îÖ°©EGFRÐźÅͨ·£¬£¬£¬½ø¶øÔö½øBITC±¬·¢ºÍÏ£Íû¡£¡£¡£ÔÚ¶¯ÎïʵÑéÖУ¬£¬£¬circ-EGFRȱʧÒÖÖÆÁËBTICµÄÖÂÁöÐÔ£¬£¬£¬Ìá¸ßÁËÄáÍ×Öéµ¥¿¹ÖÎÁÆGBMµÄЧÂÊ£¬£¬£¬Åú×¢rtEGFRÔÚEGFRÇý¶¯µÄGBMÖÐÆðÖ÷Òª×÷Óᣡ£¡£
¸ÃÑо¿Ê×´ÎϵͳÐÔ±¨µÀÁËÕæºËÉúÎïÖÐÎÞÏÞ¹ö»··Òëģʽ±¬·¢µÄ¹¦Ð§ÐÔÂѰ×ÖÊ¡£¡£¡£ÓÉÓÚcirc-EGFRÔÚBTICÖÐÏà¹ØÓÚÕý³£ÐÇÐνºÖÊϸ°û»òÉñ¾¸Éϸ°û(NSC)ÓÐÑ¡ÔñÐÔ±í´ï£¬£¬£¬Îªµ¥¿Ë¡¿¹Ìå»òС·Ö×ÓÒÖÖÆ¼Á°ÐÏòGBMÖÐrtEGFRÌṩÁËеÄÖÎÁÆÕ½ÂÔ£¨Í¼1£©¡£¡£¡£

ͼ1£º£ºrtEGFRÔÚBTICÖÐά³ÖEGFRĤ¶¨Î»²¢³ÖÐø¼¤»îEGFRÐźÅͨ·
¸ÃÑо¿Ð§¹û¡°Rolling-translated EGFR Variants Sustain EGFR Signaling and Promote Glioblastoma Tumorigenicity¡±ÔÚÏß½ÒÏþÓÚ¹ú¼Ê×ÅÃûѧÊõÆÚ¿¯ NEURO-ONCOLOGY£¨IF=10.247£¬£¬£¬JCRÒ»Çø£©¡£¡£¡£ngµç×ÓÓÎÏ·Á¥ÊôµÚһҽԺΪµÚÒ»×÷Õßµ¥Î»ºÍΨһͨѶ×÷Õßµ¥Î»£¬£¬£¬µÚÒ»×÷ÕßΪÁ¥ÊôµÚÒ»Ò½Ôº²©Ê¿ºóÁõÒí¡¢ÀîÖоüºÍÑо¿ÖúÀíÕÅïÀ×£¬£¬£¬Î¨Ò»Í¨Ñ¶×÷ÕßΪÁ¥ÊôµÚÒ»Ò½ÔºÉñ¾Íâ¿ÆÕÅåó½ÌÊÚ¡£¡£¡£ÉÏÊöÑо¿ÊÂÇé»ñµÃ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¡¢¹ú¼ÒÖØµãÑз¢ÍýÏëµÈÏîÄ¿µÄ×ÊÖú¡£¡£¡£
ÂÛÎÄÁ´½Ó£º£ºhttps://doi.org/10.1093/neuonc/noaa279